93 related articles for article (PubMed ID: 25765764)
1. LRIG1 extracellular domain: structure and function analysis.
Xu Y; Soo P; Walker F; Zhang HH; Redpath N; Tan CW; Nicola NA; Adams TE; Garrett TP; Zhang JG; Burgess AW
J Mol Biol; 2015 May; 427(10):1934-48. PubMed ID: 25765764
[TBL] [Abstract][Full Text] [Related]
2. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
Goldoni S; Iozzo RA; Kay P; Campbell S; McQuillan A; Agnew C; Zhu JX; Keene DR; Reed CC; Iozzo RV
Oncogene; 2007 Jan; 26(3):368-81. PubMed ID: 16847455
[TBL] [Abstract][Full Text] [Related]
3. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
5. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H
Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604
[TBL] [Abstract][Full Text] [Related]
6. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
Walker F; Rothacker J; Henderson C; Nice EC; Catimel B; Zhang HH; Scott AM; Bailey MF; Orchard SG; Adams TE; Liu Z; Garrett TP; Clayton AH; Burgess AW
Growth Factors; 2012 Dec; 30(6):394-409. PubMed ID: 23163584
[TBL] [Abstract][Full Text] [Related]
7. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
9. LRIG1 expression in colorectal cancer.
Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
[TBL] [Abstract][Full Text] [Related]
10. Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.
Wang Y; Shi C; Lu Y; Poulin EJ; Franklin JL; Coffey RJ
Am J Pathol; 2015 Apr; 185(4):1123-34. PubMed ID: 25794708
[TBL] [Abstract][Full Text] [Related]
11. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.
Li F; Yang W; Guo D; Hu Z; Xu H; Ye Z
Oncol Rep; 2011 Jun; 25(6):1629-37. PubMed ID: 21431282
[TBL] [Abstract][Full Text] [Related]
12. LRIG1 enhances cisplatin sensitivity of glioma cell lines.
Wang X; Xiao Q; Xing X; Tian C; Zhang H; Ye F; Wan F; Wang B; Guo D; Lei T
Oncol Res; 2012; 20(5-6):205-11. PubMed ID: 23581227
[TBL] [Abstract][Full Text] [Related]
13. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.
Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX
Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
15. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity.
Iyer AK; Tran KT; Borysenko CW; Cascio M; Camacho CJ; Blair HC; Bahar I; Wells A
J Cell Physiol; 2007 Jun; 211(3):748-58. PubMed ID: 17311283
[TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a plant leucine rich repeat protein with two island domains.
Song W; Han Z; Sun Y; Chai J
Sci China Life Sci; 2014 Jan; 57(1):137-44. PubMed ID: 24369349
[TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4].
Ye F; Guo DS; Niu HQ; Tao SZ; Ou YB; Lu YP; Lei T
Ai Zheng; 2004 Oct; 23(10):1149-54. PubMed ID: 15473925
[TBL] [Abstract][Full Text] [Related]
19. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Wu X; Hedman H; Bergqvist M; Bergström S; Henriksson R; Gullbo J; Lennartsson J; Hesselius P; Ekman S
Acta Oncol; 2012 Jan; 51(1):69-76. PubMed ID: 21417672
[TBL] [Abstract][Full Text] [Related]
20. Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling.
Hu Y; Sun Z; Eaton JT; Bouloux PM; Perkins SJ
J Mol Biol; 2005 Jul; 350(3):553-70. PubMed ID: 15949815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
